We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TD:NYSEToronto Dominion Bank (The) Analysis

Data as of 2026-06-17 - not real-time

$118.99

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at $118.99, comfortably above its 20‑day SMA (≈$113.95) and 50‑day SMA (≈$108.87), with the 200‑day SMA still well below (≈$93.28), confirming a strong bullish trend. Momentum indicators reinforce this view: the RSI sits at 75, signaling an overbought condition, while the MACD line (≈2.78) sits above its signal line (≈2.50), producing a bullish histogram. Volume, however, is decreasing, and the price is hovering near the 52‑week high and the resistance level of $119.64, suggesting limited upside. Valuation metrics paint a less rosy picture: the current price exceeds the DCF‑derived fair value of roughly $100 and the median analyst target of $112.6, yielding an upside/downside estimate of –7.8%. The forward PE of 15.5 is modestly below the industry average of 17.2, yet the trailing PE of 19.5 indicates the stock trades at a premium.
Fundamentally, the bank delivers solid profitability with an operating margin of 35% and a ROE near 12%, and earnings are accelerating (forward EPS of $7.68 versus trailing $6.10). The balance sheet is robust, featuring a low beta of 0.71 and a 30‑day volatility of 17%, but the dividend is currently absent, raising questions about income‑focused investors. Overall, the technicals support continued momentum, but valuation pressure and the lack of dividend income suggest a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near 52‑week high and resistance level
  • RSI indicating overbought conditions
  • Decreasing volume despite bullish MACD

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating margin and improving EPS
  • Forward PE below industry average
  • Valuation premium relative to DCF fair value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Solid ROE and consistent earnings growth
  • Diversified North American footprint reducing geographic concentration
  • Potential reinstatement of dividend enhancing total return

Key Metrics & Analysis

Financial Health

Revenue Growth-31.50%
Profit Margin25.19%
P/E Ratio19.5
ROE11.91%
ROA0.72%
P/B Ratio2.2
Op. Cash Flow$5.5B
Industry P/E17.2

Technical Analysis

TrendBullish
RSI75.1
Support$108.01
Resistance$119.64
MA 20$113.95
MA 50$108.87
MA 200$93.28
MACDBullish
VolumeDecreasing
Fear & Greed Index91.77

Valuation

Fair Value$99.99
Target Price$109.73
Upside/Downside-7.78%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.71
Volatility17.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.